Skip to main content
Plasma Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, Canada, China - Size and Forecast 2024-2028

Plasma Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, Canada, China - Size and Forecast 2024-2028

Published: Jul 2024 147 Pages SKU: IRTNTR73076

Market Overview at a Glance

$6.37 B
Market Opportunity
4.5%
CAGR
4.23
YoY growth 2023-2024(%)

Plasma Therapeutics Market Size 2024-2028

The plasma therapeutics market size is forecast to increase by USD 6.37 at a CAGR of 4.5% between 2023 and 2028.

  • Plasma therapeutics, a segment of the healthcare industry, is experiencing significant growth due to the increasing demand for plasma-derived proteins, particularly human immunoglobulin (HIg). The market is driven by factors such as the high demand for HIg in applications like immunology, spa therapy, and enzyme replacement therapy. Furthermore, the construction of new plasma fractionation facilities in developing economies by global players is expanding the market's reach. However, challenges persist, including the supply and demand gap for plasma and the need for advanced technologies like chromatography, membrane filtration, and salt precipitation for plasma fractionation. These techniques ensure the purity and efficacy of plasma-derived proteins, making them crucial for the industry's growth.
  • In summary, the market is witnessing robust expansion due to the rising demand for plasma-derived proteins and the establishment of new fractionation facilities, while the challenges of ensuring a consistent plasma supply and employing advanced technologies remain key areas of focus.

    • What will be the Size of the Plasma Therapeutics Market During the Forecast Period?

    Plasma Therapeutics Market Size

     Request Free Sample

  • The market encompasses the production and utilization of plasma-derived products, primarily consisting of platelets, white blood cells, red blood cells, and plasma proteIn therapies. These therapies offer effective solutions for managing chronic diseases, life-threatening conditions, and rare genetic disorders. Plasma proteIn therapies include enzymes, salts, antibodies, and immunoglobulins, addressing various medical needs such as hemostasis, coagulation factor deficiency, autoimmune disorders, cancer, and neuropathic pain. The aging population and the increasing prevalence of coronary heart disease, fibrinogen disorders (dysfibrinogenemia, afibrinogenemia, hypofibrinogenemia), and albumin deficiency further fuel market growth. Plasma therapeutics provide essential therapeutic options for a broad range of conditions, making them a vital component of modern medicine.

    • How is this Plasma Therapeutics Industry segmented and which is the largest segment?

    The plasma therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

    • Product
      • Immunoglobulin
      • Albumin
      • Blood factors
      • Others
    • Geography
      • North America
        • Canada
        • US
      • Europe
        • Germany
        • UK
      • Asia
        • China
      • Rest of World (ROW)

      By Product Insights

      • The immunoglobulin segment is estimated to witness significant growth during the forecast period.

      Plasma therapeutics encompass various treatments derived from plasma, including water, platelets, white blood cells, red blood cells, plasma proteIn therapies, and enzymes. These therapies find applications in treating chronic diseases, life-threatening conditions, and rare genetic disorders. Plasma proteins such as immunoglobulins, salts, antibodies, and proteins are produced through advanced processing methods, including source plasma collection and therapeutic options like animal bites, autoimmune disorders, immune deficiencies, neurological disorders, bleeding disorders, shocks, burns, blood transfusion, and hospital settings. The market for plasma therapeutics is driven by the increasing prevalence of immune deficiency disorders, geriatric population, hereditary autoimmune diseases, and reimbursement policies. Key conditions addressed by these therapies include cardiovascular diseases, neurological diseases, Alpha 1 Antitrypsin Deficiency, Von Willebrand Disease, Antithrombin III Deficiency, cardiopulmonary disease, hepatitis, organ transplants, liver surgery, pediatric HIV, trauma, and various inherited bleeding disorders like Hemophilia A and Hemophilia B.

      Novel therapeutics and source plasma continue to expand the therapeutic options. The market is segmented into immunoglobulin and biologics, with the immunoglobulin segment further divided into subcutaneous immunoglobulin and intravenous immunoglobulin. Key therapeutic areas include oncology, immunology, liver cirrhosis, hepatitis B, clotting factor VIII, and various coagulation factors. Fibrinogen, fibrogammin, C1 esterase inhibitors, and hyperimmune immunoglobulins are among the prominent products. Neuropathic pain, myasthenia gravis, post-polio syndrome, liver disease, malaria, sepsis, Alzheimer's disease, and subcutaneous immunoglobulin are some of the applications.

      Plasma Therapeutics Market Size

      Get a glance at the Plasma Therapeutics Industry report of share of various segments Request Free Sample

      The Immunoglobulin segment was valued at USD 13.79 in 2018 and showed a gradual increase during the forecast period.

      Regional Analysis

      • North America is estimated to contribute 40% to the growth of the global market during the forecast period.

      Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

      Plasma Therapeutics Market Share by Geography

      For more insights on the market share of various regions, Request Free Sample

      The market in North America is projected to expand at a steady rate due to the presence of a significant number of major players, including CSL Ltd., ADMA Biologics, Inc., and Pfizer Inc. The region's growth is driven by the increasing demand for plasma therapeutics in treating chronic diseases, life-threatening conditions, and rare diseases. In February 2021, the US Food and Drug Administration (FDA) approved PANZYGA, an immune globulin-based plasma therapy, for neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Similarly, in August 2021, the National Institute of Allergy and Infectious Diseases (NIAID) initiated a phase-3 clinical trial for immune globulin products from Emergent BioSolutions Inc.

      Plasma therapeutics are used to treat various conditions, including autoimmune disorders, immune deficiencies, bleeding disorders, shocks, burns, and transfusion reactions. These therapies consist of water, platelets, white blood cells, red blood cells, plasma proteIn therapies, enzymes, salts, antibodies, and proteins. Production methods and processing techniques include source plasma, therapeutic options, and novel therapeutics. Plasma therapeutics are used to treat conditions such as cardiovascular diseases, neurological diseases, Alpha 1 Antitrypsin Deficiency, Von Willebrand Disease, Antithrombin III Deficiency, cardiopulmonary disease, hepatitis, organ transplants, liver surgery, pediatric HIV, trauma, and immunoglobulin segment. The market is segmented into immunoglobulin and biologics, with the immunoglobulin segment holding the largest market share.

      Key conditions treated with immunoglobulin include hemostasis, coagulation factor deficiency, autoimmune disorders, cancer, fibrinogen, hemorrhagic diathesis, dysfibrinogenemia, afibrinogenemia, hypofibrinogenemia, albumin, and immunoglobulin. The geriatric population, hereditary autoimmune diseases, and reimbursement policies are among the significant risk factors influencing the market's growth.

      Market Dynamics

      Our  researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

      What are the key market drivers leading to the rise In the adoption of Plasma Therapeutics Industry?

      High demand for albumin in China is the key driver of the market.

    • The market encompasses various plasma-derived products, including water, platelets, white blood cells, and red blood cells. Plasma proteIn therapies are a significant segment, addressing chronic diseases, life-threatening conditions, and rare genetic diseases. Medicine relies on enzymes, salts, antibodies, and proteins derived from plasma for treating autoimmune disorders, immune deficiencies, neurological disorders, bleeding disorders, shocks, burns, and blood transfusion-related complications. The demand for plasma products, particularly albumin and immunoglobulins, is escalating due to their therapeutic applications in various conditions such as hepatitis, organ transplants, liver surgery, pediatric HIV, trauma, and inherited bleeding disorders like Hemophilia A and Hemophilia B. Novel therapeutics are also emerging, focusing on coagulation factor deficiency, autoimmune disorders, cancer, and neurological diseases.
    • However, the plasma supply is insufficient to meet the increasing demand due to stringent regulations on raw material supply and import bans. For instance, China, a significant market for albumin, has banned the import of plasma products since 1986, except for human albumin. This shortage results in higher prices and potential treatment delays, necessitating the exploration of alternative production and processing methods. Key conditions treated with plasma proteIn therapies include cardiovascular diseases, neurological diseases such as Alzheimer's disease, neuropathic pain, myasthenia gravis, and post-polio syndrome, liver disease, malaria, sepsis, and various inherited disorders like Alpha 1 Antitrypsin Deficiency, Von Willebrand Disease, and Antithrombin III Deficiency.
    • Product segmentation includes immunoglobulin, biologics, and coagulation factors. Subcutaneous immunoglobulin, fibrogammin, C1 esterase inhibitors, and primary immunodeficiency diseases are some of the notable product categories. Reimbursement policies and risk factors, including cardiovascular diseases, hepatitis, and hemostasis disorders, influence market dynamics. Conditions like fibrinogen deficiency, dysfibrinogenemia, afibrinogenemia, hypofibrinogenemia, and hepatitis B, as well as clotting factor VIII, albumin, and hyperimmune immunoglobulins, are essential therapeutic options for various conditions. Market growth is driven by the aging population, hereditary autoimmune diseases, and the increasing prevalence of immune deficiency disorders.

      • What are the market trends shaping the Plasma Therapeutics Industry?

      Establishment of plasma fractionation facilities in developing economies by global players is the upcoming market trend.

    • Plasma, a crucial component of blood, is increasingly being utilized In the production of proteIn therapies for chronic, life-threatening, and rare diseases. These therapies include enzymes, salts, antibodies, and proteins. Plasma is sourced from donors through plasma fractionation, a process that separates the plasma from the other components like platelets, white blood cells, and red blood cells. Plasma is essential in treating various conditions such as autoimmune disorders, immune deficiencies, neurological disorders, bleeding disorders, shocks, burns, and blood transfusion in hospitals. The global Plasma proteIn therapies market is expanding due to the increasing prevalence of immune deficiency disorders In the geriatric population and hereditary autoimmune diseases.
    • Furthermore, reimbursement policies and advancements in processing methods are driving market growth. Plasma is used in treating various conditions, including Alpha 1 Antitrypsin Deficiency, Von Willebrand Disease, Antithrombin III Deficiency, cardiopulmonary disease, hepatitis, organ transplants, liver surgery, pediatric HIV, trauma, and more. The Immunoglobulin segment and the Haemophilia segment are significant contributors to the market. Novel therapeutics, such as Fibrogammin, C1 esterase inhibitors, and hemophilia treatments for Hemophilia A and Hemophilia B, are gaining popularity. The market is segmented into source plasma, therapeutic options, and product segmentation. IgM antibody agonists, oncology, immunology, liver cirrhosis, hepatitis B, clotting factor VIII, alpha 1 antitrypsin, and hyperimmune immunoglobulins are some of the product segments.
    • companies are exploring opportunities in developing economies such as the Middle East, Africa, China, and India due to the availability of skilled personnel, raw materials, cheap labor, and land and a larger population base. For instance, Oryx Biotech Holdings, a China-based company, started constructing a plasma fractionation plant in Bangladesh in March 2021. This trend is expected to continue as these countries offer incentives that will attract more companies to establish facilities. Plasma is used in treating various conditions, including neuropathic pain, myasthenia gravis, post-polio syndrome, liver disease, malaria, sepsis, Alzheimer's disease, subcutaneous immunoglobulin, and more. The market dynamics include the increasing prevalence of cardiovascular diseases, neurological diseases, and coagulation factor deficiency.
    • Autoimmune disorders, cancer, and fibrinogen deficiencies such as dysfibrinogenemia, afibrinogenemia, hypofibrinogenemia, and albumin deficiency are also driving market growth.

      • What challenges does the Plasma Therapeutics Industry face during its growth?

      Existence of plasma fractionation supply and demand gap is a key challenge affecting the industry growth.

    • Plasma, a vital component of blood, is the foundation for producing essential therapeutic proteins, including platelets, white blood cells, red blood cells, and plasma proteIn therapies. These therapies offer critical solutions for individuals suffering from chronic diseases, life-threatening conditions, and rare genetic disorders. The demand for these therapies is significant, particularly for conditions like autoimmune disorders, immune deficiencies, neurological disorders, bleeding disorders, shocks, burns, and blood transfusion-related complications. Plasma proteIn therapies are derived from human plasma and cannot be synthesized artificially. The production process involves separating and purifying proteins, such as enzymes, salts, antibodies, and proteins, using various processing methods.
    • The global plasma supply, however, lags behind the demand, particularly in regions like China, where there is a high demand but a decreasing supply of human plasma. The leading players In the plasma proteIn therapeutics market include Baxter, Grifols, and CSL Behring. These companies invest in research and development to address the shortage of plasma and expand their product offerings. Plasma-derived products are used to treat various conditions, including cardiovascular diseases, neurological diseases, alpha-1 antitrypsin deficiency, Von Willebrand Disease, antithrombin III deficiency, cardiopulmonary disease, hepatitis, organ transplants, liver surgery, pediatric HIV, trauma, and inherited bleeding disorders like Hemophilia A and Hemophilia B.
    • Novel therapeutics, such as immunoglobulin segment biologics and the Haemophilia segment inherited bleeding disorder treatments, are gaining popularity due to their effectiveness and ability to address unmet medical needs. Plasma-derived therapies offer significant benefits for patients suffering from conditions like neuropathic pain, myasthenia gravis, post-polio syndrome, liver disease, malaria, sepsis, Alzheimer's disease, and subcutaneous immunoglobulin treatments for neuropathic pain and primary immunodeficiency diseases like idiopathic thrombocytopenic purpura. The aging population and the increasing prevalence of conditions like coronary heart disease, hemostasis coagulation factor deficiency, autoimmune disorders, cancer, and fibrinogen-related disorders such as dysfibrinogenemia, afibrinogenemia, hypofibrinogenemia, and albumin and immunoglobulin deficiencies further fuel the demand for plasma proteIn therapies.
    • Reimbursement policies and risk factors, such as hepatitis transmission, also impact the market dynamics. The market is segmented into product segments, including immunoglobulin, coagulation factors, fibrogammin, C1 esterase inhibitors, and hyperimmune immunoglobulins. IgM antibody agonists, oncology, immunology, liver cirrhosis, hepatitis B, clotting factor VIII, alpha 1 antitrypsin, and hyperimmune immunoglobulins are some of the key product offerings In the market.

      • Exclusive Customer Landscape

      The plasma therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the plasma therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

      Plasma Therapeutics Market Share by Geography

       Customer Landscape

      Key Companies & Market Insights

      Companies are implementing various strategies, such as strategic alliances, plasma therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

      ADMA Biologics Inc. - The market involves the production and supply of human immunoglobulin derived from donated human plasma. This protein solution is purified using a modified classical Cohn-Oncley fractionation process, ensuring high-quality and efficacy. The resulting immunoglobulin is utilized in various medical applications, including the prevention and treatment of immunodeficiencies and infectious diseases. The production process adheres to stringent regulations and quality standards, ensuring safety and reliability for healthcare providers and patients.

      The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

      • ADMA Biologics Inc.
      • Bio Products Laboratory Ltd.
      • BIOPHARMA PLASMA
      • CSL Ltd.
      • Emergent BioSolutions Inc.
      • Evolve Biologics Inc.
      • Grifols SA
      • Kamada Ltd.
      • Kedrion Spa
      • Octapharma AG
      • Pfizer Inc.
      • Prothya Biosolutions Netherlands BV
      • SK Inc.
      • Takeda Pharmaceutical Co. Ltd.

      Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

      Research Analyst Overview

      Plasma, a vital component of the human body, is a liquid part of blood that carries essential nutrients, proteins, and other elements. Plasma proteins, including antibodies, enzymes, and clotting factors, play a significant role in maintaining the body's immune response and hemostasis. Plasma therapeutics, derived from plasma, have emerged as effective treatments for various chronic diseases, life-threatening conditions, and rare genetic disorders. The market encompasses a wide range of applications, primarily focused on immune deficiency disorders, autoimmune disorders, neurological disorders, bleeding disorders, and shock conditions. Chronic diseases such as cardiovascular diseases, neurological diseases, and liver diseases are among the primary indications for plasma proteIn therapies.

      Plasma proteIn therapies are increasingly being used to address the complex medical needs of the geriatric population, who are more susceptible to various chronic diseases due to aging. These therapies offer significant benefits, including improved patient outcomes, reduced hospital stays, and lower healthcare costs. Plasma proteIn therapies are produced using advanced production and processing methods, ensuring the highest quality and safety standards. These methods include source plasma collection, fractionation, purification, and formulation. The production process ensures the preservation of essential proteins, including immunoglobulins, clotting factors, and albumin. Plasma proteIn therapies have proven effective in addressing various medical conditions.

      For instance, they are used to treat autoimmune disorders such as rheumatoid arthritis and myasthenia gravis, immune deficiency disorders like primary immunodeficiency diseases, and bleeding disorders such as hemophilia and von Willebrand disease. Plasma proteIn therapies are also used to manage shock conditions, including sepsis and trauma, and to prevent complications in organ transplants and liver surgery. Plasma proteIn therapies offer significant therapeutic benefits for patients with chronic diseases. For instance, they help manage neuropathic pain, improve hemostasis in coagulation factor deficiency, and provide immunoglobulin replacement therapy for patients with primary immunodeficiency diseases. Plasma proteIn therapies are also used to treat rare genetic disorders, such as alpha 1 antitrypsin deficiency and dysfibrinogenemia.

      The plasma proteIn therapies market is segmented into various product segments, including immunoglobulins, clotting factors, and albumin. The immunoglobulin segment is further segmented into IgG, IgM, and IgA antibody agonists. The clotting factor segment includes factors VIII, IX, X, XI, and XIII. The albumin segment is used for volume replacement therapy and wound healing. Plasma proteIn therapies offer significant therapeutic benefits for various medical conditions. However, they come with certain risks, including allergic reactions, anaphylaxis, and transmission of infectious diseases. Reimbursement policies and risk factors associated with plasma proteIn therapies are critical considerations for healthcare providers and payers.

      In conclusion, plasma proteIn therapies offer significant therapeutic benefits for various medical conditions, including immune deficiency disorders, autoimmune disorders, neurological disorders, bleeding disorders, and shock conditions. The plasma proteIn therapies market is expected to grow significantly due to the increasing prevalence of chronic diseases and the aging population. Advanced production and processing methods ensure the highest quality and safety standards, making plasma proteIn therapies an essential component of modern medicine.

      Market Scope

      Report Coverage

      Details

      Page number

      147

      Base year

      2023

      Historic period

      		 2018-2022

      Forecast period

      2024-2028

      Growth momentum & CAGR

      Accelerate at a CAGR of 4.5%

      Market growth 2024-2028

      USD 6.37 billion

      Market structure

      Concentrated

      YoY growth 2023-2024(%)

      4.23

      Key countries

      US, Germany, UK, Canada, and China

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Request Free Sample

      What are the Key Data Covered in this Plasma Therapeutics Market Research and Growth Report?

      • CAGR of the Plasma Therapeutics industry during the forecast period
      • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
      • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
      • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
      • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
      • Thorough analysis of the market’s competitive landscape and detailed information about companies
      • Comprehensive analysis of factors that will challenge the plasma therapeutics market growth of industry companies

      We can help! Our analysts can customize this plasma therapeutics market research report to meet your requirements.

      Get in touch

       

      Table of Contents not available.

      Research Methodology

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      INFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases

      DATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts

      REPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape

      Interested in this report?

      Get your sample now to see our research methodology and insights!

      Download Now

      Frequently Asked Questions

      Plasma Therapeutics market growth will increase by $ 6.37 bn during 2024-2028.

      The Plasma Therapeutics market is expected to grow at a CAGR of 4.5% during 2024-2028.

      Plasma Therapeutics market is segmented by Product( Immunoglobulin, Albumin, Blood factors, Others)

      ADMA Biologics Inc., Bio Products Laboratory Ltd., BIOPHARMA PLASMA, CSL Ltd., Emergent BioSolutions Inc., Evolve Biologics Inc., Grifols SA, Kamada Ltd., Kedrion Spa, Octapharma AG, Pfizer Inc., Prothya Biosolutions Netherlands BV, SK Inc., Takeda Pharmaceutical Co. Ltd. are a few of the key vendors in the Plasma Therapeutics market.

      North America will register the highest growth rate of 40% among the other regions. Therefore, the Plasma Therapeutics market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

      US, Germany, UK, Canada, China

      • High demand for albumin in ChinaChina is one of the largest markets for albumin products in the global plasma therapeutics market is the driving factor this market.
      • followed by the US market. Albumin is being used as a volume replacement therapy apart from being used for kidney diseases is the driving factor this market.
      • cirrhosis is the driving factor this market.
      • and cancer. However is the driving factor this market.
      • the demand for plasma products is the driving factor this market.
      • especially albumin and immunoglobulins is the driving factor this market.
      • is outstripping the supply. This is because of the stringent regulations imposed on the supply of raw materials and a ban on the import of plasma products. For instance is the driving factor this market.
      • since 1986 is the driving factor this market.
      • the Government of China has forbidden all plasma and blood-derived products from being imported into China is the driving factor this market.
      • with the exception of human albumin. Due to the increased demand for albumin products is the driving factor this market.
      • the ban on the import of plasma products is not imposed on albumin. Also is the driving factor this market.
      • the well-established players have extensive growth opportunities due to high demand and the increased entry barriers for new players. Therefore is the driving factor this market.
      • vendors are focusing on strategic alliances to expand their presence in China. For instance is the driving factor this market.
      • in March 2020 is the driving factor this market.
      • Grifols and Shanghai RAAS formed a strategic alliance in China. With this development is the driving factor this market.
      • Grifols increased the number of plasma centers in China to 41. This vast difference in demand and supply is enabling the top players to enhance their market presence in China is the driving factor this market.
      • thereby increasing their revenues. Such factors are expected to drive the growth of the market during the forecast period. is the driving factor this market.

      The Plasma Therapeutics market vendors should focus on grabbing business opportunities from the Immunoglobulin segment as it accounted for the largest market share in the base year.